BIOMAT Database Logo BIOMAT Database Logo

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. 2003

Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel

UI MeSH Term Description Entries
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment.
December 1994, Journal of hepatology,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Incidence of hepatitis B reactivation following Rituximab therapy.
March 2009, American journal of hematology,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Prevention of hepatitis B virus reactivation under rituximab therapy.
November 2009, Immunotherapy,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy.
January 2018, Frontiers in medicine,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Reactivation of hepatitis B virus with rituximab.
May 2005, Expert opinion on drug safety,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
January 2011, Journal of gastroenterology,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Preventing hepatitis B virus reactivation following immunosuppressive therapy.
July 2008, Internal medicine journal,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Hepatitis B virus reactivation with rituximab-containing regimen.
November 2013, World journal of hepatology,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Hepatitis B escape mutant reactivation in a renal transplant patient.
September 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Timm H Westhoff, and Friederike Jochimsen, and Alexander Schmittel, and Marina Stoffler-Meilicke, and Jurgen H Schafer, and Walter Zidek, and Wolfram H Gerlich, and Eckhard Thiel
Precore mutant hepatitis B reactivation after treatment with CHOP-rituximab.
January 2005, Anti-cancer drugs,
Copied contents to your clipboard!